| Literature DB >> 19399161 |
Goodarz Danaei1, Eric L Ding, Dariush Mozaffarian, Ben Taylor, Jürgen Rehm, Christopher J L Murray, Majid Ezzati.
Abstract
BACKGROUND: Knowledge of the number of deaths caused by risk factors is needed for health policy and priority setting. Our aim was to estimate the mortality effects of the following 12 modifiable dietary, lifestyle, and metabolic risk factors in the United States (US) using consistent and comparable methods: high blood glucose, low-density lipoprotein (LDL) cholesterol, and blood pressure; overweight-obesity; high dietary trans fatty acids and salt; low dietary polyunsaturated fatty acids, omega-3 fatty acids (seafood), and fruits and vegetables; physical inactivity; alcohol use; and tobacco smoking. METHODS ANDEntities:
Mesh:
Year: 2009 PMID: 19399161 PMCID: PMC2667673 DOI: 10.1371/journal.pmed.1000058
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Risk factors in this analysis, their exposure variables, theoretical-minimum-risk exposure distributions, disease outcomes, and data sources for exposure.
| Risk Factor | Exposure Metric | Exposure Data Sources | TMRED±SD | Disease Outcomes |
|
| Usual level of fasting plasma glucose | NHANES 2003–2006 (SD corrected for intra-individual variation) | 4.9±0.3 mmol/l | IHD; stroke; renal failure; |
|
| Usual level of LDL cholesterol | NHANES 2003–2006 (SD corrected for intra-individual variation) | 2.0±0.44 mmol/l | IHD; ischemic stroke; |
|
| Usual level of systolic blood pressure | NHANES 2003–2006 (SD corrected for intra-individual variation) | 115±6 mmHg | IHD, stroke, hypertensivedisease, other cardiovascular diseases |
|
| BMI | NHANES 2003–2006 | 21±1 kg/m2
| IHD; ischemic stroke; hypertensive disease; diabetes mellitus; corpus uteri, colon, kidney, and postmenopausal breast cancers; |
|
| Usual percent of total calories from dietary trans fatty acids | CSFII 1989–1991 | 0.5%±0.05% of total calories from trans fatty acids | IHD |
|
| Usual percent of total calories from dietary PUFA | NHANES 2003–2006 | 10%±1% of total calories from PUFA | IHD, stroke |
|
| Usual dietary omega-3 fatty acids in five categories adjusted for total calories | NHANES 2003–2006 | 250 mg/d | IHD, stroke |
|
| Usual level of dietary sodium adjusted for total calories | NHANES 2003–2006 | 0.5±0.05 g/d | IHD, stroke, hypertensivedisease, other cardiovascular diseases, stomach cancer, |
|
| Usual dietary fruit and vegetable intake adjusted for total calories | NHANES 2003–2006 | 600±50 g/d | IHD; ischemic stroke; colorectal, stomach, lung, esophagus, mouth, and pharyngeal cancers |
|
| Current alcohol consumption volumes and patterns | NESARC 2001–2002, FARS 2005 and emergency room studies | No alcohol use | IHD; ischemic stroke; hemorrhagic stroke; hypertensive disease; cardiac arrhythmias; diabetes mellitus; liver, mouth, and pharynx, larynx, breast, esophagus, colorectal, selected other cancers |
|
| Physical activity measured in four categories: inactive, low-active, moderately active, and highly active | NHANES 2003–2006 | The whole population being highly active (≥1 h/wk of vigorous activity and at least 1,600 met·min/wk) | IHD; ischemic stroke; breast cancer and colon cancers; diabetes mellitus |
|
| Current levels of Smoking Impact Ratio (SIR) (indirect indicator of accumulated smoking risk based on excess lung cancer mortality) | Lung cancer mortality from adjusted vital registration in 2004 | No smoking | IHD; stroke; selected other cardiovascular diseases; diabetes mellitus; lung, esophagus, mouth and pharynx, stomach, liver, pancreas, cervix, bladder, kidney and other urinary cancers; leukemia; chronic obstructive pulmonary disease (COPD); other respiratory diseases |
Outcomes in italics are those for which the effects were not quantified in the main analysis due to weaker evidence on causality (e.g. tobacco smoking and colorectal cancer or high blood glucose and cancers) or because there were very few deaths from the disease (e.g. high BMI and gallbladder cancer).
We evaluated sensitivity to the choice of exposure metric by using total cholesterol instead of LDL-cholesterol (Table S1).
Two alternative TMREDs for LDL cholesterol with means of 1.6 mmol/l and 2.3 mmol/l were examined in sensitivity analysis (Table S1).
This category includes rheumatic heart disease, acute and subacute endocarditis, cardiomyopathy, other inflammatory cardiac diseases, valvular disorders, aortic aneurysm, pulmonary embolism, conduction disorders, peripheral vascular disorders, and other ill-defined cardiovascular diseases.
We did not include some of the cancers that were found to have significant association with BMI in a recent meta-analysis [17] either because there were very few deaths in the US (adenocarcinoma of esophagus and gallbladder cancer) or because there was not strong evidence on a causal effect from other studies (leukemia and multiple myeloma). We included non-Hodgkin lymphoma in a sensitivity analysis (Table S1).
The NHANES rounds in 2003–2006 include a 2-d dietary intake survey and could be used to estimate dietary trans fatty acids. However, a reliable source for the trans fat content of each food item was not available to us. We have used the intake estimates in the Continuing Survey of Food Intakes by Individuals (CSFII) 1989–1991 [68] in our analysis.
Omega-3 intake categories in the analysis were: 0 to <62.5; 62.5 to <125; 125 to <187.5; 187.5 to <250; and ≥250 mg/d of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
The effect of reduction in salt intake on SBP and the effect of subsequent decline in SBP on the relevant disease outcomes were estimated at the individual level to account for possible correlation between salt intake and SBP.
We evaluated sensitivity to the assumption of normal distribution for fruit and vegetable intake (Table S1).
Exposure categories were: Abstainer, a person not having had a drink containing alcohol within the last year; DI, 0–19.99 g of pure alcohol daily (females) and 0–39.99 g (males); DII, 20–39.99 g (females) and 40–59.99 g (males); and DIII, >40 g (females) and >60 g (males). Binge drinking was defined as having at least one occasion of five or more drinks in the last month.
An alternative TMRED for alcohol use as regular drinking of small amounts of alcohol is considered in sensitivity analysis (Table S1).
This category includes ICD-9 codes 210–239.
This category includes ICD-9 codes 291, 303, and 305.0.
Categories of physical activity were defined as below using responses to questions regarding physical activity during the past 30 d: inactive, no moderate or vigorous physical activity; low-active, <2.5 h/wk of moderate activity or <600 met·min/wk; moderately active, either ≥2.5 h/wk of moderate activity or ≥1 h of vigorous activity and ≥600 met·min/wk; highly active, ≥1 h/wk of vigorous activity and ≥1,600 met·min/wk.
This TMRED is based on multiple prospective studies that report beneficial effects of physical activity continuing above the current recommended levels [69]–[72].
We also calculated the mortality effects of tobacco smoking using the prevalence of current and former smokers, as used by Smoking-Attributable Mortality, Morbidity, and Economic Costs (SAMMEC; http://apps.nccd.cdc.gov/sammec) [73], in a sensitivity analysis (Table S1).
This category includes lower respiratory tract infections and asthma.
Evidence of a causal association between tobacco smoking and colorectal cancer was classified as suggestive in the 2004 Report of the US Surgeon General [73]. The 2004 report also excluded hypertensive disease from the outcomes considered in smoking-attributable mortality. Therefore, colorectal cancer and hypertensive disease were not included in the main analysis, but were included in sensitivity analysis (Table S1).
Sources and magnitudes of relative risks for the effects of continuous dietary risk factors on disease-specific mortality.
| Risk Factor | Disease Outcome | Source of RR | Units | Age Group | RR |
|
| IHD | Meta-analysis of three prospective cohort studies | Per one percentage point more calories | 30–44 | 1.40 |
| 45–59 | 1.29 | ||||
| 60–69 | 1.14 | ||||
| 70–79 | 1.08 | ||||
| 80+ | 1.06 | ||||
|
| IHD | Meta-analysis of seven intervention studies by authors | Per one percentage point less calories from PUFA, in isocaloric exchange for SFA | 30–44 | 1.05 |
| 45–59 | 1.04 | ||||
| 60–69 | 1.02 | ||||
| 70–79 | 1.01 | ||||
| 80+ | 1.01 | ||||
|
| SBP | Meta-analysis of dietary trials | mmHg SBP per 100 mmol/d dietary sodium | SBP≥140 mmHg | 7.11 |
| SBP<140 mmHg | 3.57 | ||||
| Stomach cancer | Meta-analysis of three prospective cohort studies | Per 100 mmol/d dietary sodium | — | 1.57 | |
|
| IHD | Meta-analysis of six prospective cohort studies | Per 80 g/d lower intake | 30–69 | 1.04 |
| 70–79 | 1.03 | ||||
| 80+ | 1.02 | ||||
| Ischemic stroke | Meta-analysis of three prospective cohort studies | Per 80 g/d lower intake | 30–69 | 1.06 | |
| 70–79 | 1.05 | ||||
| 80+ | 1.03 | ||||
| Lung cancer | Meta-analysis of major observational studies | Per 80 g/d lower intake | 30–69 | 1.04 | |
| 70–79 | 1.03 | ||||
| 80+ | 1.02 | ||||
| Stomach cancer | Meta-analysis of major observational studies | Per 80 g/d lower intake | 30–69 | 1.06 | |
| 70–79 | 1.05 | ||||
| 80+ | 1.03 | ||||
| Colorectal cancer | Meta-analysis of major observational studies | Per 80 g/d lower intake | 30–69 | 1.01 | |
| 70–79 | 1.01 | ||||
| 80+ | 1.00 | ||||
| Esophagus, mouth, and pharynx cancers | Meta-analysis of major observational studies | Per 80 g/d lower intake | 30–69 | 1.10 | |
| 70–79 | 1.08 | ||||
| 80+ | 1.05 |
For these risk factor–disease pairs, RRs in the source were reported for all ages combined. We used median age at event and the age pattern of excess risk for serum total cholesterol and IHD to estimate RRs for each age category.
The interventions studies replaced dietary SFA with PUFA, hence the RRs measure the effect of replacement. Effects of replacing PUFA for other macronutrients have not been evaluated in randomized interventions studies. However, evidence from cohort studies suggests that replacement of PUFA for carbohydrates, but not carbohydrates for SFA, would produce similar benefits [78], indicating that the measured benefits are due to PUFA.
Sources and magnitudes of relative risks (RRs) for the effects of categorical dietary risk factors on disease-specific mortality.
| Risk Factor | Disease Outcome | Source of RR | Age Group | RR 1 | RR 2 | RR 3 | RR 4 | RR 5 |
|
| IHD | Meta-analysis of randomized intervention studies and prospective cohort studies | 30–44 | 2.18 | 1.80 | 1.46 | 1.14 | 1.00 |
| 45–59 | 1.86 | 1.58 | 1.33 | 1.10 | 1.00 | |||
| 60–69 | 1.41 | 1.28 | 1.16 | 1.05 | 1.00 | |||
| 70–79 | 1.23 | 1.16 | 1.09 | 1.03 | 1.00 | |||
| 80+ | 1.19 | 1.13 | 1.07 | 1.02 | 1.00 | |||
| Stroke | Meta-analysis of 12 prospective cohort studies by authors | 30–44 | 1.27 | 1.19 | 1.11 | 1.04 | 1.00 | |
| 45–59 | 1.27 | 1.19 | 1.11 | 1.04 | 1.00 | |||
| 60–69 | 1.16 | 1.11 | 1.06 | 1.02 | 1.00 | |||
| 70–79 | 1.11 | 1.08 | 1.04 | 1.01 | 1.00 | |||
| 80+ | 1.10 | 1.07 | 1.04 | 1.01 | 1.00 |
Omega-3 intake categories in the analysis were (1) 0 to <62.5; (2) 62.5 to <125; (3) 125 to <187.5; (4) 187.5 to <250; and (5) ≥250 mg/d of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
For each disease outcome, RRs in the source were reported for all ages combined. We used median age at event and the age pattern of excess risk for serum total cholesterol and the same disease to estimate RRs for each age category.
RRs were summarized via meta-regression across intake levels [79]. When RRs were reported for fish intake, we converted the units to omega 3 intake using the average omega-3 content of one serving of fish estimated using NHANES 2003–2004.
Sources and magnitudes of relative risks for the effects of alcohol use on disease-specific mortality.
| Disease Outcome | Source of RR | Age Group | Sex | Abstainers | DI | DII | DIII | Binge Drinkers |
|
| Meta-analysis of observational studies for non-binge | 30–44 | — | 1.00 | 0.60 | 0.62 | 1.00 | 1.00 |
| 45–59 | — | 1.00 | 0.63 | 0.65 | 1.00 | 1.00 | ||
| 60–69 | — | 1.00 | 0.82 | 0.83 | 1.00 | 1.00 | ||
| 70–79 | — | 1.00 | 0.92 | 0.93 | 1.00 | 1.00 | ||
| 80+ | — | 1.00 | 0.97 | 0.98 | 1.00 | 1.00 | ||
|
| Meta-analysis of 35 observational studies | 30–44 | M | 1.00 | 0.83 | 0.83 | 3.84 | — |
| F | 1.00 | 0.88 | 1.07 | 1.33 | — | |||
| 45–59 | M | 1.00 | 0.88 | 0.88 | 2.52 | — | ||
| F | 1.00 | 0.91 | 1.05 | 1.22 | — | |||
| 60–69 | M | 1.00 | 0.94 | 0.94 | 1.69 | — | ||
| F | 1.00 | 0.96 | 1.02 | 1.10 | — | |||
| 70–79 | M | 1.00 | 0.97 | 0.97 | 1.32 | — | ||
| F | 1.00 | 0.98 | 1.01 | 1.05 | — | |||
| 80+ | M | 1.00 | 1.00 | 1.00 | 1.00 | — | ||
| F | 1.00 | 1.00 | 1.00 | 1.00 | — | |||
|
| Meta-analysis of 35 observational studies | 30–44 | M | 1.00 | 1.65 | 3.16 | 6.65 | — |
| F | 1.00 | 1.30 | 2.07 | 3.89 | — | |||
| 45–59 | M | 1.00 | 1.42 | 2.21 | 3.60 | — | ||
| F | 1.00 | 1.20 | 1.67 | 2.54 | — | |||
| 60–69 | M | 1.00 | 1.19 | 1.55 | 2.18 | — | ||
| F | 1.00 | 1.09 | 1.30 | 1.70 | — | |||
| 70–79 | M | 1.00 | 1.09 | 1.25 | 1.55 | — | ||
| F | 1.00 | 1.04 | 1.13 | 1.32 | — | |||
| 80+ | M | 1.00 | 1.00 | 1.00 | 1.00 | — | ||
| F | 1.00 | 1.00 | 1.00 | 1.00 | — | |||
|
| Overview of observational studies | — | M | 1.00 | 1.4 | 2.0 | 4.1 | — |
| — | F | 1.00 | 1.4 | 2.0 | 2.0 | — | ||
|
| Overview of observational studies | — | — | 1.00 | 1.51 | 2.23 | 2.23 | — |
|
| Systematic review of epidemiological studies | 30–44 | F | 1.00 | 1.15 | 1.41 | 1.46 | — |
| 45+ | F | 1.00 | 1.14 | 1.38 | 1.62 | — | ||
|
| Pooled analysis of 8 prospective cohort studies | — | M | 1.00 | 1.0 | 1.16 | 1.41 | — |
| — | F | 1.00 | 1.0 | 1.01 | 1.41 | — | ||
|
| Overview of observational studies | — | — | 1.00 | 1.80 | 2.38 | 4.36 | — |
|
| Overview of observational studies | — | — | 1.00 | 1.45 | 1.85 | 5.39 | — |
|
| Overview of observational studies | — | — | 1.00 | 1.83 | 3.90 | 4.93 | — |
|
| Overview of observational studies | — | — | 1.00 | 1.45 | 3.03 | 3.60 | — |
|
| Overview of observational studies | — | — | 1.00 | 1.1 | 1.3 | 1.7 | — |
|
| Overview of observational studies | — | M | 1.00 | 0.99 | 0.57 | 0.73 | — |
| — | F | 1.00 | 0.92 | 0.85 | 1.13 | — | ||
|
| Overview of observational studies | — | — | 1.00 | 1.3 | 9.5 | 13 | — |
|
| Meta-analysis of observational studies | — | M | 1.00 | 1.3 | 1.8 | 3.2 | — |
| — | F | 1.00 | 1.3 | 1.8 | 1.8 | — | ||
| BAC % | <0.01 | 0.01–0.04 | 0.05–0.07 | 0.08–0.1 | ≥0.11 | |||
|
| Grand Rapids Study | OR | 1.0 | 1.2 | 1.7 | 4.0 | 10.7 | |
|
| Grand Rapids Study | OR | 10.7 | — | — | — | — |
Exposure categories were: Abstainer, a person not having had a drink containing alcohol within the last year; DI 0–19.99 g of pure alcohol daily (females) and 0–39.99 g (males); DII, 20–39.99 g (females) and 40–59.99 g (males); and DIII, >40 g (females) and >60 g (males). Binge drinking was defined as having at least one occasion of five or more drinks in the last month. For IHD, the categories refer to non-binge drinkers.
For these risk factor–disease pairs, RRs in the source were reported for all ages combined. We used median age at event and the age pattern of excess risk from smoking and the same disease to estimate RRs for each age category.
This category includes ICD-9 codes 210–239.
These odds ratios were used to estimate PAF as described in the Methods section.
Used to estimated PAF for having drunk alcohol in the last 6 h before injury.
Sources and magnitudes of relative risks for the effects of physical inactivity on disease-specific mortality.
| Disease Outcome | Source of RR | Age Group | Highly Active | Recommended Level Active | Insufficiently Active | Inactive |
|
| Meta-analysis of 20 prospective cohort studies | 30–69 | 1.00 | 1.15 | 1.66 | 1.97 |
| 70–79 | 1.00 | 1.15 | 1.51 | 1.73 | ||
| 80+ | 1.00 | 1.15 | 1.38 | 1.50 | ||
|
| Meta-analysis of 8 prospective cohort studies | 30–69 | 1.00 | 1.12 | 1.23 | 1.72 |
| 70–79 | 1.00 | 1.12 | 1.21 | 1.55 | ||
| 80+ | 1.00 | 1.12 | 1.18 | 1.39 | ||
|
| Meta-analysis of 12 prospective cohort and 31 case-control studies | 30–44 | 1.00 | 1.25 | 1.41 | 1.56 |
| 45–69 | 1.00 | 1.25 | 1.41 | 1.67 | ||
| 70–79 | 1.00 | 1.25 | 1.36 | 1.56 | ||
| 80+ | 1.00 | 1.25 | 1.32 | 1.45 | ||
|
| Meta-analysis of 11 prospective cohort and 19 case-control studies | 30–69 | 1.00 | 1.07 | 1.27 | 1.80 |
| 70–79 | 1.00 | 1.07 | 1.21 | 1.59 | ||
| 80+ | 1.00 | 1.07 | 1.16 | 1.39 | ||
|
| Meta-analysis of 13 prospective cohort and 9 case-control studies | 30–69 | 1.00 | 1.21 | 1.50 | 1.76 |
| 70–79 | 1.00 | 1.21 | 1.43 | 1.60 | ||
| 80+ | 1.00 | 1.21 | 1.34 | 1.45 |
Categories of physical activity were defined as below using responses to questions regarding physical activity during the past 30 d: inactive, no moderate or vigorous physical activity; low-active, <2.5 h/wk of moderate activity or <600 met·min/wk; moderately active: either ≥2.5 h/wk of moderate activity or ≥1 h of vigorous activity and ≥600 met·min/wk; highly active: ≥1 h/wk of vigorous activity and ≥1,600 met·min/wk.
The meta-analysis of RRs for physical inactivity used three categories: inactive, insufficiently active, and recommended-level active. For this analysis, we re-scaled the RRs to set the highly active group as the reference category. The ratio of excess risk from recommended-level active to high-active was from Manson et al. for IHD [69], Hu et al. for ischemic stroke [70], Patel et al. 2003 for breast cancer [71], and Chao et al. for colon cancer [72].
Sources and magnitudes of relative risks for the effects of tobacco smoking on disease-specific mortality.
| Disease Outcome | Source of RR | Age Group | Sex | RR |
|
| American Cancer Society Cancer Preventions Study, Phase II (ACS CPS-II) | 30–44 | M | 5.51 |
| F | 2.26 | |||
| 45–59 | M | 3.04 | ||
| F | 3.78 | |||
| 60–69 | M | 1.88 | ||
| F | 2.53 | |||
| 70–79 | M | 1.44 | ||
| F | 1.68 | |||
| 80+ | M | 1.05 | ||
| F | 1.38 | |||
|
| ACS CPS-II | 30–44 | M | 3.12 |
| F | 4.61 | |||
| 45–59 | M | 3.12 | ||
| F | 4.61 | |||
| 60–69 | M | 1.88 | ||
| F | 2.81 | |||
| 70–79 | M | 1.39 | ||
| F | 1.95 | |||
| 80+ | M | 1.05 | ||
| F | 1.00 | |||
|
| ACS CPS-II | 30–44 | M | 5.93 |
| F | 2.38 | |||
| 45–59 | M | 3.23 | ||
| F | 4.05 | |||
| 60–69 | M | 1.96 | ||
| F | 2.67 | |||
| 70–79 | M | 1.48 | ||
| F | 1.74 | |||
| 80+ | M | 1.06 | ||
| F | 1.42 | |||
|
| ACS CPS-II | 30–44 | M | 6.91 |
| F | 2.65 | |||
| 45–59 | M | 3.68 | ||
| F | 4.65 | |||
| 60–69 | M | 2.15 | ||
| F | 3.00 | |||
| 70–79 | M | 1.58 | ||
| F | 1.89 | |||
| 80+ | M | 1.07 | ||
| F | 1.50 | |||
|
| Meta-analysis of 25 prospective cohort studies with 1.2 million participants | — | — | 1.44 |
|
| ACS CPS-II | — | M | 21.3 |
| F | 12.5 | |||
|
| ACS CPS-II | — | M | 8.1 |
| F | 6.0 | |||
|
| ACS CPS-II | — | M | 2.16 |
| F | 1.49 | |||
|
| ACS CPS-II | — | M | 2.33 |
| F | 1.50 | |||
|
| ACS CPS-II | — | — | 2.20 |
|
| ACS CPS-II | — | F | 1.50 |
|
| ACS CPS-II | — | M | 3.00 |
| F | 2.40 | |||
|
| ACS CPS-II | — | M | 1.89 |
| F | 1.23 | |||
|
| ACS CPS-II | — | M | 1.32 |
| F | 1.41 | |||
|
| ACS CPS-II | — | M | 2.5 |
| F | 1.5 | |||
|
| ACS CPS-II | — | M | 10.8 |
| F | 12.3 | |||
|
| ACS CPS-II | — | M | 1.90 |
| F | 2.20 | |||
|
| Meta-analysis of cohort, case-control, and cross-sectional studies | — | — | 1.62 |
We used ACS CPS-II as the source of RRs because the Smoking Impact Ratio (SIR), which was used as the exposure metric for tobacco smoking in the main analysis, is calculated using ACS CPS-II cohort and because the study provided separate RRs for different cancers and cardiovascular diseases by age. The CPS-II RRs were also adjusted for multiple potential confounders.
For these disease outcomes, RRs in the source were reported for all ages combined. We used median age at event and the age pattern of excess risk from IHD to estimate RRs for each age category.
This category includes lower respiratory tract infections and asthma.
Sources and magnitudes of relative risks for the effects of metabolic risk factors on disease-specific mortality.
| Risk Factor | Disease Outcome | Source of RR | Units | Age Group | Sex | RR |
|
| IHD | Meta-analysis of 19 prospective cohort studies with 237,000 participants | Per mmol/l increase | 30–59 | — | 1.42 |
| 60–69 | — | 1.20 | ||||
| 70+ | — | 1.20 | ||||
| Stroke | Meta-analysis of 19 prospective cohort studies with 237,000 participants | Per mmol/l increase | 30–59 | — | 1.36 | |
| 60–69 | — | 1.28 | ||||
| 70+ | — | 1.08 | ||||
| Renal failure | Randomized trial of 3,900 participants | Per mmol/l increase | — | 1.26 | ||
|
| IHD | Meta-analysis of ten prospective cohort studies | Per mmol/l increase | 30–44 | — | 2.94 |
| 45–59 | — | 2.10 | ||||
| 60–69 | — | 1.59 | ||||
| 70–79 | — | 1.27 | ||||
| 80+ | — | 1.01 | ||||
| Ischemic stroke | Meta-analysis of nine prospective cohort studies | Per mmol/l increase | 30–44 | — | 1.30 | |
| 45–59 | — | 1.30 | ||||
| 60–69 | — | 1.18 | ||||
| 70–79 | — | 1.00 | ||||
| 80+ | — | 1.00 | ||||
|
| IHD | PSC meta-analysis of 61 prospective cohort studies with 900,000 European and North American participants | Per mmol/l increase | 30–44 | — | 2.11 |
| 45–59 | — | 1.81 | ||||
| 60–69 | — | 1.39 | ||||
| 70–79 | — | 1.22 | ||||
| 80+ | — | 1.18 | ||||
| Ischemic stroke | PSC | Per mmol/l increase | 30–44 | — | 1.51 | |
| 45–59 | — | 1.37 | ||||
| 60–69 | — | 1.12 | ||||
| 70–79 | — | 1.00 | ||||
| 80+ | — | 1.00 | ||||
|
| IHD | PSC | Per 20 mmHg increase | 30–44 | — | 2.04 |
| 45–59 | — | 2.01 | ||||
| 60–69 | — | 1.85 | ||||
| 70–79 | — | 1.67 | ||||
| 80+ | — | 1.49 | ||||
| Stroke | PSC | Per 20 mmHg increase | 30–44 | — | 2.55 | |
| 45–59 | — | 2.74 | ||||
| 60–69 | — | 2.33 | ||||
| 70–79 | — | 2.00 | ||||
| 80+ | — | 1.49 | ||||
| Hypertensive disease | PSC | Per 20 mmHg increase | 30–44 | — | 4.78 | |
| 45–59 | — | 5.02 | ||||
| 60–69 | — | 4.55 | ||||
| 70–79 | — | 4.10 | ||||
| 80+ | — | 3.50 | ||||
| Other cardiovascular diseases | PSC | Per 20 mmHg increase | 30–44 | — | 2.52 | |
| 45–59 | — | 2.11 | ||||
| 60–69 | — | 1.89 | ||||
| 70–79 | — | 1.56 | ||||
| 80+ | — | 1.43 | ||||
|
| IHD | APCSC meta-analysis of 33 prospective cohorts with 310,000 participants | Per kg/m2 increase | 30–44 | — | 1.14 |
| 45–59 | — | 1.09 | ||||
| 60–69 | — | 1.08 | ||||
| 70–79 | — | 1.05 | ||||
| 80+ | — | 1.02 | ||||
| Ischemic stroke | APCSC | Per kg/m2 increase | 30–44 | — | 1.14 | |
| 45–59 | — | 1.10 | ||||
| 60–69 | — | 1.08 | ||||
| 70–79 | — | 1.05 | ||||
| 80+ | — | 1.03 | ||||
| Hypertensive disease | APCSC | Per kg/m2 increase | 30–44 | — | 1.22 | |
| 45–59 | — | 1.18 | ||||
| 60–69 | — | 1.14 | ||||
| 70–79 | — | 1.11 | ||||
| 80+ | — | 1.08 | ||||
| Postmenopausal breast cancer | Meta-analysis of 31 prospective cohort studies | Per kg/m2 increase | 45+ | F | 1.02 | |
| Colon cancer | Meta-analysis of 22 prospective cohort studies in males and 19 in females | Per kg/m2 increase | — | M | 1.04 | |
| F | 1.02 | |||||
| Corpus uteri cancer | Meta-analysis of 19 prospective cohort studies | Per kg/m2 increase | — | F | 1.10 | |
| Kidney cancer | Meta-analysis of 11 prospective cohort studies in males and 12 in females | Per kg/m2 increase | — | 1.05 | ||
| Pancreatic cancer | Meta-analysis of 12 prospective cohort studies in males and 11 in females | Per kg/m2 increase | — | M | 1.01 | |
| F | 1.02 | |||||
| Non-Hodgkin lymphoma (sensitivity analysis) | Meta-analysis of six prospective cohort studies in males and seven in females | Per kg/m2 increase | — | — | 1.01 | |
| Diabetes mellitus | APCSC meta-analysis prospective cohort studies with 150,000 participants | Per kg/m2 increase | 30–59 | — | 1.20 | |
| 60–69 | — | 1.16 | ||||
| 70+ | — | 1.11 |
See Danaei et al. [61] for sensitivity to using RRs from systematic reviews of other epidemiological studies.
For these risk factor–disease pairs, RRs in the source were reported for all ages combined. We used median age at event and the age pattern of excess risk from another risk factor and the same disease (e.g., age pattern of total serum cholesterol and ischemic stroke was applied to LDL and ischemic stroke) or from the same risk factor and another disease (e.g., age pattern of excess risk for SBP and all cardiovascular diseases was applied to SBP and hypertensive disease) to estimate RRs for each age category.
We used a null association in those 70-y-old and older because RRs in two large meta-analyses of prospective studies [95], [97] were not statistically significant from null, and did not show consistent benefits for lower total cholesterol in these ages. There is some evidence from clinical trials that statins reduce the risk of stroke in older ages [98]. However, statins may reduce stroke mortality through other, non-cholesterol mechanisms such as stabilization of atherosclerotic plaques [99]. In the sensitivity analysis for high LDL cholesterol and ischemic stroke, we used an RR of 1.12 in these age groups.
This category includes rheumatic heart disease, acute and subacute endocarditis, cardiomyopathy, other inflammatory cardiac diseases, valvular disorders, aortic aneurysm, pulmonary embolism, conduction disorders, peripheral vascular disorders, and other ill-defined cardiovascular diseases.
We used meta-analyses of studies with measured weight and height because using self-reported weight and height can lead to bias in estimated RRs. The correlation between self-reported and measured weight, as found in selected studies [100], [101], does not remove the possibility of bias because even with perfect correlation, the absolute bias in self-reported weight and height may be a function of its true value.
The RRs reported for Asian and Australia–New Zealand populations were not significantly different in this meta-analysis providing empirical evidence on absence of significant effect modification in the multiplicative scale by ethnicity. A meta-analysis of studies in Europe and North America included studies [102] with self-reported height and weight and was thus not used in this analysis. The RRs reported in that meta-analysis ranged from 1.02 to 1.26 and the average RR weighted by number of cases was 1.07 per kg/m2 which is almost equal to the RR for 60- to 69-y-olds in this analysis.
APCSC, Asia-Pacific Cohorts Studies Collaboration; PSC, Prospective Studies Collaboration.
Figure 1Deaths attributable to total effects of individual risk factors, by disease.
Data are shown for both sexes combined (upper graph); men (middle graph); and women (lower graph). See Table 8 for 95% CIs. Notes: We used RRs for blood pressure, LDL cholesterol, and FPG that were adjusted for regression dilution bias using studies that had repeated exposure measurement [7],[11],[12]; for blood pressure and LDL cholesterol, the adjusted magnitude is supported by effect sizes from randomized studies [13],[14]. Evidence from a large prospective study using multiple measurements of weight and height showed that regression dilution bias did not affect the RRs for BMI, possibly because there is less variability [15]. RRs for dietary salt and PUFA were from intervention studies, and hence unlikely to be affected by regression dilution bias. RRs for dietary trans fatty acids were primarily from studies that had used cumulative averaging of repeated measurements [16] that reduces but may not fully correct for regression dilution bias. RRs for physical inactivity, alcohol use, smoking, and dietary omega-3 fatty acids and fruits and vegetables were not corrected for regression dilution bias due to insufficient current information from epidemiological studies on exposure measurement error and variability, which is especially important when error and variability of self-reported exposure may themselves differ across studies. Regression dilution bias often, although not always, underestimates RRs in multivariate analysis [48]. aThe figures show deaths attributable to the total effects of each individual risk. There is overlap between the effects of risk factors because of multicausality and because the effects of some risk factors are partly mediated through other risks. Therefore, the number of deaths attributable to individual risks cannot be added. bThe effect of high dietary salt on cardiovascular diseases was estimated through its measured effects on systolic blood pressure. cThe protective effects of alcohol use on cardiovascular diseases are its net effects. Regular moderate alcohol use is protective for IHD, ischemic stroke, and diabetes, but any use is hazardous for hypertensive disease, hemorrhagic stroke, cardiac arrhythmias, and other cardiovascular diseases. NCD, noncommunicable diseases.
Deaths from all causes (thousands of deaths) attributable to risk factors and the 95% confidence intervals of their sampling uncertainty.
| Risk factor | Male | Female | Both Sexes |
| Tobacco smoking | 248 (226–269) | 219 (196–244) | 467 (436–500) |
| High blood pressure | 164 (153–175) | 231 (213–249) | 395 (372–414) |
| Overweight–obesity (high BMI) | 114 (95–128) | 102 (80–119) | 216 (188–237) |
| Physical inactivity | 88 (72–105) | 103 (80–128) | 191 (164–222) |
| High blood glucose | 102 (80–122) | 89 (69–108) | 190 (163–217) |
| High LDL cholesterol | 60 (42–70) | 53 (44–59) | 113 (94–124) |
| High dietary salt (sodium) | 49 (46–51) | 54 (50–57) | 102 (97–107) |
| Low dietary omega-3 fatty acids (seafood) | 45 (37–52) | 39 (31–47) | 84 (72–96) |
| High dietary trans fatty acids | 46 (33–58) | 35 (23–46) | 82 (63–97) |
| Alcohol use | 45 (32–49) | 20 (17–22) | 64 (51–69) |
| Low intake of fruits and vegetables | 33 (23–45) | 24 (15–36) | 58 (44–74) |
| Low dietary polyunsaturated fatty acids (PUFA) (in replacement of SFA) | 9 (6–12) | 6 (3–9) | 15 (11–20) |
Excludes uncertainty in intentional and unintentional injury outcomes because the attributable deaths used data sources that did not report sampling uncertainty.
Distribution of cause-specific and all-cause deaths attributable to risk factors by age group and by sex.
| Risk Factor | Disease | 0–29 y | 30–45 y | 45–69 y | ≥ 70 y | Males | Females |
|
| Cardiovascular diseases | NA | 2 (1 to 3) | 31 (24 to 40) | 68 (58 to 75) | 55 (43 to 68) | 45 (32 to 57) |
| Diabetes mellitus | NA | 3 (3 to 3) | 33 (33 to 33) | 64 (64 to 64) | 51 (51 to 51) | 49 (49 to 49) | |
| Renal failure | NA | 1 (0 to 6) | 21 (3 to 71) | 77 (26 to 96) | 53 (12 to 94) | 47 (6 to 88) | |
| All causes | NA | 2 (2 to 3) | 31 (26 to 36) | 67 (61 to 72) | 53 (46 to 61) | 47 (39 to 54) | |
|
| Cardiovascular diseases | NA | 4 (0 to 6) | 40 (30 to 47) | 55 (50 to 66) | 53 (44 to 59) | 47 (41 to 56) |
|
| Cardiovascular diseases | NA | 1 (1 to 1) | 19 (18 to 20) | 80 (79 to 82) | 42 (39 to 44) | 58 (56 to 61) |
|
| Cardiovascular diseases | NA | 5 (3 to 6) | 41 (33 to 48) | 55 (47 to 63) | 55 (47 to 65) | 45 (35 to 53) |
| Cancers | NA | 2 (2 to 3) | 42 (38 to 47) | 55 (51 to 60) | 40 (36 to 46) | 60 (54 to 64) | |
| Diabetes mellitus | NA | 5 (4 to 5) | 42 (38 to 47) | 54 (48 to 58) | 52 (46 to 58) | 48 (42 to 54) | |
| All causes | NA | 4 (3 to 5) | 41 (36 to 46) | 55 (49 to 61) | 53 (47 to 60) | 47 (40 to 53) | |
|
| Cardiovascular diseases | NA | 5 (3 to 7) | 41 (31 to 50) | 54 (45 to 65) | 57 (46 to 67) | 43 (33 to 54) |
|
| Cardiovascular diseases | NA | 7 (2 to 11) | 40 (23 to 56) | 53 (37 to 70) | 59 (43 to 75) | 41 (25 to 57) |
|
| Cardiovascular diseases | NA | 4 (3, 5) | 36 (30 to 41) | 60 (54 to 66) | 53 (47 to 60) | 47 (40 to 53) |
|
| Cardiovascular diseases | NA | 3 (3 to 3) | 28 (27 to 30) | 69 (67 to 70) | 47 (45 to 50) | 53 (50 to 55) |
| Cancers | NA | 5 (1 to 8) | 36 (21 to 52) | 59 (43 to 74) | 58 (40 to 73) | 42 (27 to 60) | |
| All causes | NA | 3 (3 to 3) | 29 (27 to 30) | 68 (66 to 70) | 48 (45 to 50) | 52 (50 to 55) | |
|
| Cardiovascular diseases | NA | 3 (1 to 5) | 35 (22 to 52) | 62 (44 to 75) | 55 (37 to 76) | 45 (24 to 63) |
| Cancers | NA | 3 (2 to 5) | 56 (39 to 71) | 41 (25 to 58) | 62 (47 to 76) | 38 (24 to 53) | |
| All causes | NA | 3 (2 to 5) | 43 (32 to 57) | 54 (39 to 66) | 58 (45 to 71) | 42 (29 to 55) | |
|
| Cardiovascular diseases | NA | 11 (4 to 34) | 131 (93 to 159) | −42 (−75 to −7) | 105 (85 to 126) | −5 (−26 to 15) |
| Cancers | NA | 5 (4 to 6) | 55 (49 to 61) | 40 (34 to 46) | 64 (58 to 69) | 36 (31 to 42) | |
| Diabetes mellitus | NA | 5 (4 to 6) | 44 (40 to 49) | 51 (46 to 55) | 50 (45 to 55) | 50 (45 to 55) | |
| Other noncommunicable diseases | NA | 15 (14 to 16) | 68 (66 to 71) | 17 (15 to 19) | 74 (72 to 76) | 26 (24 to 28) | |
| Injuries | 31 (31 to 31) | 34 (34 to 34) | 29 (29 to 29) | 6 (6 to 6) | 77 (77 to 77) | 23 (23 to 23) | |
| All causes | 18 (16 to 23) | 24 (21 to 30) | 34 (20 to 40) | 24 (20 to 30) | 70 (62 to 73) | 30 (27 to 38) | |
|
| Cardiovascular diseases | NA | 2 (1 to 2) | 24 (19 to 30) | 74 (68 to 79) | 49 (40 to 60) | 51 (40 to 60) |
| Cancers | NA | 5 (3 to 7) | 42 (35 to 50) | 53 (45 to 60) | 24 (18 to 29) | 76 (71 to 82) | |
| Diabetes mellitus | NA | 3 (2 to 5) | 35 (28 to 43) | 61 (52 to 69) | 50 (40 to 61) | 50 (39 to 60) | |
| All causes | NA | 2 (2 to 3) | 28 (23 to 33) | 70 (64 to 75) | 46 (38 to 54) | 54 (46 to 62) | |
|
| Cardiovascular diseases | NA | 4 (0 to 7) | 51 (43 to 63) | 44 (34 to 54) | 49 (38 to 60) | 51 (40 to 62) |
| Cancers | NA | 1 (0 to 2) | 43 (42 to 44) | 56 (55 to 57) | 61 (60 to 62) | 39 (38 to 40) | |
| Other respiratory diseases | NA | 0 (0 to 1) | 21 (19 to 22) | 79 (78 to 80) | 46 (44 to 48) | 54 (52 to 56) | |
| Diabetes mellitus | NA | 1 (0 to 3) | 36 (30 to 41) | 63 (57 to 68) | 50 (44 to 57) | 50 (43 to 56) | |
| All causes | NA | 2 (0 to 3) | 39 (36 to 42) | 59 (56 to 62) | 53 (49 to 57) | 47 (43 to 51) |
Numbers show percent in each age group or in each sex and the corresponding 95% confidence intervals of sampling uncertainty.
There is no sampling uncertainty for this outcome because all the deaths due to diabetes are by definition attributable to high blood glucose.
The negative proportions for alcohol use and cardiovascular diseases in older ages and in females occur because the protective effects are larger than the hazardous effects.
This category includes liver cirrhosis, acute and chronic pancreatitis, and alcohol use disorders.
We did not estimate sampling uncertainty for injury outcomes because the attributable deaths used data sources that did not report sampling uncertainty.
This category includes lower respiratory tract infections, asthma, and tuberculosis.
Figure 2Deaths attributable to total effects of individual risk factors, by disease in those below 70 years of age.
Data are shown for both sexes combined (upper graph); men (middle graph); and women (lower graph). See Figure 1 notes.
Distribution of risk factor exposure and attributable deaths by ranges or categories of exposure defined using common clinical and public health thresholds and guidelines.
| Risk Factor | Source of Definition for Categories | Exposure Categories | Percentage of Attributable Deaths | Percentage of Population (≥30 Years Old) |
|
| Definition of diabetes (FPG≥7 mmol/l) and impaired FPG (FPG 5.56 to 6.99 mmol/l) by American Diabetes Association | FPG≥7 mmol/l | 60 | 10 |
| FPG 5.56–6.99 mmol/l | 34 | 29 | ||
| FPG<5.56 mmol/l | 6 | 61 | ||
|
| Definition of high LDL cholesterol in low risk (4.14 mmol/l) and moderate risk (3.37 mmol/l) individuals in Adult Treatment Panel III guidelines | LDL≥4.14 mmol/l | 5 | 11 |
| LDL 3.37–4.13 mmol/l | 30 | 22 | ||
| LDL<3.37 mmol/l | 65 | 67 | ||
|
| Definition of hypertension (SBP≥140 mmHg) | SBP≥140 mmHg | 66 | 15 |
| SBP<140 mmHg | 34 | 85 | ||
|
| Definition of obesity (BMI≥30 kg/m2) and overweight (BMI 25 to 29.9 kg/m2) | BMI≥30 kg/m2 | 63 | 33 |
| BMI 25–29.9 kg/m2 | 29 | 33 | ||
| BMI<25 kg/m2 | 8 | 33 | ||
|
| Recommended level of dietary sodium (<100 mmol/d) by American Heart Association | Dietary sodium≥100 mmol/d | 88 | 75 |
| Dietary sodium<100 mmol/d | 12 | 25 | ||
|
| Definition of moderately active (600 met·min/wk) is the same as the recommended level of activity by Centers for Disease Control and Prevention | Inactive | 74 | 31 |
| Low-active | 19 | 25 | ||
| Moderately active | 7 | 23 | ||
| Highly active | 0 | 21 | ||
|
| — | Current smokers | 43 | 25 |
| Former smokers | 57 | 25 | ||
| Never smokers | 0 | 50 |
The proportion of population and mortality effects in different exposure categories. We have not included dietary risks other than dietary salt in this table primarily because current guidelines do not recommend a specific level of intake.
Deaths assigned to diabetes mellitus in the vital statistics and deaths attributable to renal failure are included in the ≥7 mmol/l category because all individuals whose deaths are assigned to diabetes or diabetic renal failure would, by definition, have been diagnosed with diabetes disease, and hence have FPG ≥7 mmol/l.